News

Unreliable respondents are the scourge of consumer panels. Our data shows that cheaters and bots typically represent the majority of commercially available diabetes patient sample. We routinely see them in healthcare provider sample as well.

Our Qual team has conducted thousands of interviews with patients and medical professionals. We map patient journeys, test and refine diabetes devices in development, assess communication effectiveness and uncover prescribing drivers and barriers.

Our latest Diabetes Drug Insights study follows a group of more than n=3,000 people with type 2 diabetes in the USA from 2018 to 2024.

The latest data in our current survey highlights geographical differences in the comorbidities experienced by people with diabetes along with satisfaction with their glucose control.

People with Type 1 diabetes (PWT1) in Europe (EU) and the United States (USA) generally have similar access to diabetes technologies. So how do their health outcomes compare? dQ&A’s work shows that even with similar treatment plans, differing regional factors influencing diabetes management — such as obesity levels and the cost and accessibility of healthcare — potentially affect patient wellness.

In fifteen years of diabetes research, we’ve learned a lot about what drives successful outcomes...

New dQ&A data tracks GLP-1 & SGLT2 trends, patient/HCP insights, satisfaction, and market shifts to guide diabetes drug decisions.

Our research finds that 37% of people with diabetes report poor quality sleep, and about half suffer from restless sleep or have trouble staying asleep.